Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity.

ABSTRACT: The efficacy of cancer immunotherapy depends on the fine interplay between tumoral immune checkpoints and host immune system. However, the up-to-date clinical performance of checkpoint blockers in cancer therapy revealed that higher-level regulation should be further investigated for better therapeutic outcomes. It is becoming increasingly evident that the expression of immune checkpoints is largely associated to the immunotherapeutic response and consequent prognosis. Deubiquitinating enzymes (DUBs) with their role of cleaving ubiquitin from proteins and other molecules, thus reversing ubiquitination-mediated protein degradation, modulate multiple cellular processes, including, but not limited to, transcriptional regulation, cell cycle progression, tissue development, and antiviral respon

SUBMITTER: Huang X 

PROVIDER: S-EPMC7426525 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature